<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib0049">
 <element-citation publication-type="journal" id="sbref0049">
  <person-group person-group-type="author">
   <name>
    <surname>Guo</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Xue</surname>
    <given-names>Q.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Ge</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>Q.</given-names>
   </name>
   <name>
    <surname>Cai</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Shan</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>J.</given-names>
   </name>
  </person-group>
  <article-title>Dimethylaminomicheliolide (DMAMCL) Suppresses the Proliferation of Glioblastoma Cells via Targeting Pyruvate Kinase 2 (PKM2) and Rewiring Aerobic Glycolysis</article-title>
  <source>Frontiers in Oncology</source>
  <volume>9</volume>
  <year>2019</year>
  <fpage>993</fpage>
  <pub-id pub-id-type="doi">10.3389/fonc.2019.00993</pub-id>
  <pub-id pub-id-type="pmid">31632919</pub-id>
 </element-citation>
</ref>
